Podcasts about chemoprevention

HEALTH NEWS   ·         Antioxidant combination supports cognition, muscle ·         Berberine for Chemoprevention of Colon Polyps ·         Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis, finds study ·         Ruminating About Stressful Events May Increase Inflammation In The Body ·         Topical Frankincense Relieves Knee Osteoarthritis Pain and Stiffness ·         Great, Now Band-Aids Pose Cancer Risk Thanks To ‘Forever Chemicals'

This podcast explores the genetic determinants and mechanisms of breast and ovarian cancer. Jonathan and Sofia Merajver, Michigan Medicine, Ann Arbor, USA, discuss brain metastases, the severity of inflammatory breast cancer, and the movement of cancers through tissue. Use the following timestamps to navigate this episode! (00:00)-Introduction (02:27)-Sofia's journey into medicine (04:10)-Personal stakes (05:09)-Not being your doctor (06:58)-Genes in inflammatory breast cancer (10:58)-RHO proteins (12:52)-Brain metastasis (17:33)-Crossing the blood–brain barrier (22:11)-Aggressive phenotypes of breast cancer (24:18)-Chemoprevention in breast cancer

This week we sit down with Sotirios-Charalampos (Sotiris) Diamantoudis, Maria Vasileiou, and Elpida Lytra to discuss the new NCODA Greece PSO Chapter, Oncology in Greece, and the Cancer Prevention Research Group Greece.Sotirios-Charalampos (Sotiris) Diamantoudis is a 2nd-year Pharmacy student at the Aristotle University of Thessaloniki, Greece. His passion for oncology has led him to take the position of Co-Head of Chemoprevention, Nutritional Supplements, and Cancer at the Cancer Prevention Research Group in Greece. When he first encountered NCODA in Athens during the 18th European Pharmaceutical Students' Association Autumn Assembly, where he volunteered, he considered the initiative of most interest and immediately joined in. Taking it a step further, Sotiris notified his network to spread NCODA and its values in Greece. Maria Vasileiou is a 4th-year pharmacy student at National and Kapodistrian University of Athens. Her area of interest is cancer research, which includes primary and secondary prevention, chemoprevention, and the association of dietary supplements and medicines with cancer incidence and progression. She has hands-on experience in cancer research, having attended a postgraduate program on immunotherapy in advanced/metastatic urothelial carcinoma. She serves as Co-Founder and President-Elect of NCODA Greece.Elpida Lytra is a 5th-year Pharmacy student at the Aristotle University of Thessaloniki, Greece. She serves as Director of Finances at NCODA Greece.You can follow NCODA Greece on Instagram @ncodagreece or on LinkedIn: https://www.linkedin.com/company/ncodagreece/.

In this podcast of the December issue of Dermatologic Surgery, published by the American Society for Dermatologic Surgery, you'll hear a summary of the original articles, reconstructive conundrums, and communications. Contributors to this podcast include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Monica Boen, MD; Deirdre Connolly, MD; Ashley Decker, MD; Ami Green, MD; Deirdre Hooper, MD; Isabella Jones, MD; Erica Leavitt, MD; Karan Lal, DO; Ardalan Minokadeh, MD, PhD; Christie Regula, MD; and Michael Renzi, MD. BONUS CONTENT – Beyond the Digest Beyond the Digest is bonus content that includes the review of interesting and relevant articles from the Beyond the Digest is bonus content that includes the review of interesting and relevant articles from the Journal of the American Medical Association Dermatology and the Journal of the American Academy of Dermatology. The December Beyond the Digest includes article reviews from the Journal of the American Academy of Dermatology. Retrospective analysis of the MAUDE database on dermal filler complications from 2014-2020 Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma Merkel cell carcinoma treatment with Mohs micrographic surgery versus wide local excision: A retrospective cohort survival analysis Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: A randomized, double-blind, placebo-controlled pilot trial Surgical site infections due to razor-mediated hair removal in dermatologic surgery: A retrospective cohort study Risk factors for postoperative wound dehiscence after skin repair: A case-control study Beyond the Digest Contributors include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Elizabeth Cusick, MD; Ami Greene, MD; Harrison Shawa, MD; and Yesul Kim, MD. Your feedback is encouraged. Please contact communicationstaff@asds.net with any suggestions for improvement.

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit https://myriad.com/live/ for a list of dates, times, and subjects.

Host: Jacob Sands, MD Guest: Marie Wood, MD Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.

@michaelsalzle. Treatment implications of cancer. Chemoprevention, and the emerging treatments of cancer, including CTLA 4 inhibitors, PD 1 inhibitors, and CAR T.

Guest: Professor Rajendra Maharaj See omnystudio.com/listener for privacy information.

This episode is hosted by Dr. Thomas Slavin (T.J.) and features Dr. Eduardo Vilar-Sanchez. Dr. Vilar-Sanchez is a medical oncologist at MD Anderson Cancer Center. Together they discuss “Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa,” which was published in Gut and found here: https://pubmed.ncbi.nlm.nih.gov/32641470/ This episode was recorded on March 26, 2021 and reflects expert opinion at the time of the recording.

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the July 21, 2020 issue

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Worldwide there are 550,000 new cases of head and neck cancer a year. Dr. Jennifer Grandis explores prevention and an opportunity for chemo prevention, substances to stop cancer from developing. In particular, she looks at aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). Series: "Mini Medical School for the Public" [Show ID: 35237]

Prostate cancer: how common, how to detect it, how to treat it (should we?) // Artificial lights and sleep with Morgan Sweeney // Should we really be eating more meat now?   * Vox pop by David Lonstein * Jingle by Joseph Hackl of Voodoo Jazz * Additional music by Seth Donnelly and Kevin MacLeod of Incompetech.com (including "House of Leaves"). * Theme music: "Troll of the Mountain Swing" by the Underscore Orkestra.   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/.   Patrons get a bonus show on Patreon called “Digressions”! Check it out!   References: 1) ERSPC randomized trial of prostate cancer screening: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.eururo.2012.05.068 2) ERSPC randomized trial of prostate cancer screening: https://www.ncbi.nlm.nih.gov/pubmed/30824296 3) Quality of Life study: https://www.nejm.org/doi/full/10.1056/NEJMoa1201637 4) Chemoprevention study 1, PCPT: https://www.nejm.org/doi/full/10.1056/NEJMoa1215932 5) Chemoprevention study 2, REDUCE: https://www.nejm.org/doi/full/10.1056/NEJMoa0908127 6) Surgery vs. radiation vs. active surveillance: https://www.nejm.org/doi/full/10.1056/NEJMoa1606220

Rosacea diagnosis relies on clinical judgment. Dr. Vincent DeLeo talks to Dr. William James about rosacea classification and its controversies. Dr. James describes the evolution of rosacea classification systems and the need to define the clinical features of rosacea to improve patient care. “There is no gold-standard laboratory diagnosis for [rosacea],” Dr. James explains. “It’s really a diagnosis that’s made on clinical criteria, so those criteria I think should be well defined.” We also bring you the latest dermatology news and research. 1. Beyond sunscreen: Skin cancer preventive agents finding a role A growing list of skin cancer chemopreventive agents is expanding options for risk management. 2. Psoriasis patients on biologics show improved heart health Novel imaging biomarker identifies reduced coronary inflammation in psoriasis patients on biologics. 3. Dupilumab found effective for adolescents with moderate to severe atopic dermatitis The rates of skin infections also were higher in the placebo group, compared with the treatment groups. Things you will learn in this episode: There are three published rosacea classification systems based on clinical presentation, including the original classification schema introduced by the National Rosacea Society in 2002 and updated in 2018 as well as a similar classification system published by the global ROSacea COnsensus panel in 2017. The initial classification system included a list of primary and secondary features that were considered diagnostic of rosacea, but no standardized group of characteristics has been shown to be applicable in all cases of rosacea. The newer classification systems focus more on identifying phenotypic changes in rosacea patients rather than classifying subtypes of disease, as not every rosacea patient presents with a classic constellation of symptoms. Targeting individual symptoms of rosacea allows for more specific treatments based on a patient’s unique clinical presentation rather than designing therapies for broad subtypes. Despite advancements made in the newer classification systems, some of the definitions of primary features of classification still require more refinement; for instance, the classifications address flushing in rosacea as a very quick reaction, occurring within seconds to minutes of a trigger, but they do not address the prolonged nature of the redness, which is not as transient as in people who are simply embarrassed or overheated from exercise. Although it was included in the initial classification schema, granulomatous rosacea was eliminated in the newer classifications, likely because it does not share commonalities with traditional rosacea presentations. When diagnosing rosacea, it is important to consider other disease states that can lead to a red face and are in fact associated with diagnostic laboratory values or histopathologic appearances, such as systemic lupus, dermatomyositis, mastocytosis, carcinoid syndrome, polycythemia vera, and diabetes, as these conditions are more serious from a systemic standpoint. New treatment algorithms for rosacea focus on treating specific phenotypes rather than groups of symptoms, leading to more targeted therapies that can be used to treat individual patient presentations. Hosts: Elizabeth Mechcatie, Terry Rudd, Vincent A. DeLeo, MD (Keck School of Medicine of the University of Southern California, Los Angeles) Guest: William D. James, MD (University of Pennsylvania School of Medicine, Philadelphia) Show notes by: Alicia Sonners, Melissa Sears, Elizabeth Mechcatie You can find more of our podcasts at http://www.mdedge.com/podcasts      Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeDerm

Interview with Martin A. Weinstock, author of Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial

Dr Ford talks to ecancertv at the 2015 World Oncology Forum about the work being done in chemoprevention and vaccination in breast and prostate cancer. Her work focuses on chemical interventions rather than lifestyle. In particular, she mentions 'Prostvac', an anti-prostate cancer vaccine which is currently being trialled.

Prof Coleman speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about bone-targeted agents that have links to reducing breast cancer incidence. He describes results from trials of bisphosphonate and denosumab, a well tolerated antibody which inhibits RANK ligand pathways. Prof Coleman also relates the ongoing IBIS III study of bisphosphonates to reduce recurrence and relapse of breast cancer, and considers the future of chemoprevention in health care.

Dr Din speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about her research into the metabolic processes of aspirin in cancer cells Using organoid models, she reports on the mechanisms by which aspirin inhibits mTOR signalling and protein regulation. Dr Din describes the additional impacts of diet, exercise and genetic susceptibility on tumour metabolism, and the population-level outcomes that wider adoption of chemoprevention could contribute towards.

Prof Patrono speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about the action of COX1 in preventing colorectal cancer. Platelet activation, stimulated by COX1, results in angiogenesis which supports tumoural development. Prof Patrono also describes how platelets may form a physical barrier around tumours, and how aspirin can directly obstruct a serine residue essential for platelet function.

Dr Censi speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about the hurdles facing adoption of chemopreventative strategies. He highlights the lack of monetary and emotional investment in prevention compared to diagnosis and treatment of cancers, and the uncertainty surrounding clinical data due to the lengthy timeline of studies. Dr Cesni also considers the regulatory issues of off-brand prescription and repurposing of drugs, compared to the widespread public acceptance of food supplements, and the incorporation of preventative behaviours into screening and counselling.

Norris Cotton Cancer Center Grand Rounds - Ronald Lubet, PhD National Cancer Institute

Prof Patrono speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about the action of COX1 in preventing colorectal cancer. Platelet activation, stimulated by COX1, results in angiogenesis which supports tumoural development. Prof Patrono also describes how platelets may form a physical barrier around tumours, and how aspirin can directly obstruct a serine residue essential for platelet function.

Prof Coleman speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about bone-targeted agents that have links to reducing breast cancer incidence. He describes results from trials of bisphosphonate and denosumab, a well tolerated antibody which inhibits RANK ligand pathways. Prof Coleman also relates the ongoing IBIS III study of bisphosphonates to reduce recurrence and relapse of breast cancer, and considers the future of chemoprevention in health care.

Dr Din speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about her research into the metabolic processes of aspirin in cancer cells Using organoid models, she reports on the mechanisms by which aspirin inhibits mTOR signalling and protein regulation. Dr Din describes the additional impacts of diet, exercise and genetic susceptibility on tumour metabolism, and the population-level outcomes that wider adoption of chemoprevention could contribute towards.

Dr Censi speaks with ecancertv at the 2016 BACR and ECMC Joint Meeting about the hurdles facing adoption of chemopreventative strategies. He highlights the lack of monetary and emotional investment in prevention compared to diagnosis and treatment of cancers, and the uncertainty surrounding clinical data due to the lengthy timeline of studies. Dr Cesni also considers the regulatory issues of off-brand prescription and repurposing of drugs, compared to the widespread public acceptance of food supplements, and the incorporation of preventative behaviours into screening and counselling.

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. Chen AC1, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. N Engl J Med. 2015 Oct 22;373(17):1618-26. doi: 10.1056/NEJMoa1506197.

Chemoprevention with guest Dr. Erin Hofstatter December 21, 2014 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Runtime 90:00 Dr. Max Gomez leads a panel discussion on genetic counseling and cancer care for people with hereditary forms of cancer. read more

Prof Richard Logan talks to ecancer at the 2013 Aspirin Foundation meeting in Oxford about chemoprevention in bladder cancer and screening programmes across the UK and Europe.

Howard H. Bailey, MD, University of Wisconsin Carbone Cancer Center, reviews green tea polyphenols and their relation to GU cancer chemoprevention.

In this podcast, you'll receive a definition of chemoprevention, what these medications can and cannot do, and how they are being studied. We'll also look at some examples of chemoprevention that are being used or studied for their potential benefit in preventing cancer. Cancer Screening and Prevention

In this podcast, you'll receive a definition of chemoprevention, what these medications can and cannot do, and how they are being studied. We'll also look at some examples of chemoprevention that are being used or studied for their potential benefit in preventing cancer.

Despite clear results of observational studies linking a diet rich in fruits and vegetables to a decreased cancer risk, large interventional trials evaluating the impact of dietary micronutrient supplementation, mostly vitamins, could not show any beneficial effects. Today it has become clear that a single micronutrient, given in supernutritional doses, cannot match cancer preventive effects of whole fruits and vegetables. In this regard polyphenols came into focus, not only because of their antioxidant potential but also because of their ability to interact with molecular targets within the cells. Because polyphenols occur in many foods and beverages in high concentration and evidence for their anticancer activity is best for tissues they can come into direct contact with, field cancerization predestines upper aerodigestive tract epithelium for cancer chemoprevention by polyphenols. In this paper, we summarize cancer chemopreventive attempts with emphasis on head and neck carcinogenesis and discuss some methodological issues. We present data regarding antimutagenic effects of curcumin and epigallocatechin-3-gallate in human oropharyngeal mucosa cultures exposed to cigarette smoke condensate.

Presented by Andrew Stephenson, MD, FRCSC, FACS Cheif, Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic